Bausch Health Companies Inc. reported a profit of US$71 million for its third-quarter compared with a loss of US$49 million in the same quarter last year as revenue was hurt by the pandemic.
The Quebec-based drug company, which keeps its books in U.S. dollars, says the profit amounted to 20 cents per share for the quarter ended Sept. 30 compared with a loss of 14 cents per share in the third quarter of 2019.
Revenue totalled US$2.14 billion, down from US$2.21 billion a year ago.
The company says the COVID-19 pandemic hurt revenue by about US$150 million in the quarter.
Bausch Health says its adjusted earnings before interest, taxes, depreciation and amortization were US$948 million for the third quarter of 2020 compared with US$942 million for the third quarter of 2019.
The company, formerly known as Valeant Pharmaceuticals, manufactures and sells a range of pharmaceutical, medical device and over-the-counter products, mostly related to eye health, gastroenterology and dermatology.
Your time is valuable. Have the Top Business Headlines newsletter conveniently delivered to your inbox in the morning or evening. Sign up today.